Who is sponsoring NCT00656630?

NCT00656630 is sponsored by The Scripps Research Institute.

What condition does NCT00656630 study?

NCT00656630 studies Alcoholism.

What drugs are being tested in NCT00656630?

Interventions: Acamprosate, Naltrexone, Placebo.

What is the status of NCT00656630?

NCT00656630 is currently COMPLETED.

Last reviewed 2017-02-08 · How we verify

Medication Development in Protracted Abstinence in Alcoholism: Acamprosate Versus Naltrexone

NCT00656630 Phase 2 COMPLETED Results posted

The purpose of this study is to develop and validate a human laboratory model for prediction of medication efficacy in clinical trials for relapse prevention in alcohol dependence.

Details

Lead sponsor	The Scripps Research Institute
Phase	Phase 2
Status	COMPLETED
Enrolment	68
Start date	2007-12
Completion	2010-01

Conditions

Alcoholism

Interventions

Acamprosate
Naltrexone
Placebo

Primary outcomes

Visual Analog Scale of Craving to Drink at 1 Week Following Administration of Acamprosate or Naltrexone or Placebo During the Double-Blind Period — 1 week
The four Visual Analog Scale questions assess domains of alcohol craving: the intention to drink, loss of control, relief craving, and urge intensity. The scale ranges from 0-20 where a zero indicates no craving and 20 indicates severe craving; thus, a higher score indicates a worse outcome. Total is a summation of the four subscales (i.e. Strength, Intent, Impulse, Relief) and ranges in value from 0-80 with higher scores indicative of a worse outcome.

Countries

United States